<DOC>
	<DOCNO>NCT01535729</DOCNO>
	<brief_summary>This prospective observational study evaluate efficacy safety Tarceva ( erlotinib ) elderly patient advance non-small cell lung cancer ( NSCLC ) failure least one prior chemotherapy regimen . Data patient treat Tarceva routine clinical practice collect 1 year .</brief_summary>
	<brief_title>An Observational Study Tarceva ( Erlotinib ) Elderly Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patient , &gt; 65 year age Locally advance metastatic nonsmall cell lung cancer ( Stage IIIb IV ) Failure least one prior standard platinumbased chemotherapy Age &lt; 65 year</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>